Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dpb-T is an experimental small molecule belonging to the class of organic compounds known as pyrimidones, which contain a pyrimidine ring. Its chemical formula is C17H19N2O8P and it has a molecular weight of approximately 410.3 g/mol. The primary known biological target for Dpb-T is the human mitochondrial enzyme 5'(3')-deoxyribonucleotidase (gene name NT5M), which dephosphorylates specifically the 5' and 2'(3')-phosphates of uracil and thymine deoxyribonucleotides, thereby protecting mitochondrial DNA replication from excess dTTP. It has only marginal activity towards dIMP and dGMP. The compound is classified as experimental, with no approved therapeutic indications or marketed formulations currently available[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dpb-T.